Clinical stage oncology company Avacta Group has moved its Therapeutics division to a new headquarters in London.
The headquarters will be based at Scale Space in Imperial College’s White City Campus, London. Scale Space is part of the broader White City Innovation District. White City is currently home to over 140 companies across a broad range of industries including pharmaceutical and biotech.
Avacta intends for the new headquarters to bring together its research and development teams to support the continued growth of the company’s pre-clinical and clinical development pipelines of cancer therapies. The move follows the transition of AVA6000, the company’s lead pre|CISION targeted chemotherapy programme and a tumour activated form of doxorubicin, into the clinic in August 2021.
Official comments
Dr Fiona McLaughlin, Chief Scientific Officer of Avacta, said: “This move is the result of a clear vision to bring together the research and development teams into one hub to facilitate the translation of our in-house research from bench to bedside. We are now at the heart of the innovative White City community in London, readily accessible to our collaborators around the world and poised to take Avacta to the next level in its evolution as a clinical stage biopharmaceutical company.”
Neil Bell, Chief Development Officer of Avacta, added: “The relocation of Avacta’s Therapeutics division to Scale Space in the heart of Imperial College’s White City Campus is a transformative milestone for our business, as we take the next steps towards developing our innovative oncology pipeline and improving our ability to bring these innovative therapies through to patients. This new location gives Avacta access to world class facilities, increased opportunities for collaboration and access to a significant talent pool to take the business forward.”
